Skip to content

Use of Continuous Wound Infusion of Bupivacaine for Analgesia Following Axillary Clearance Surgery

Does Continuous Wound Infusion of 0.2% Bupivacaine Provide Superior Analgesia Compared to Standard Opioid-based Therapy in Patients Following Axillary Clearance Surgery?

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01314144
Enrollment
42
Registered
2011-03-14
Start date
2010-08-31
Completion date
2011-10-31
Last updated
2011-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

axillary clearance, wound infiltration, wound infusion, local anaesthetic wound infusion

Brief summary

Axillary clearance forms part of the surgical armamentarium for the treatment of breast cancer. Although the introduction of sentinel lymph node mapping and dissection has allowed for the decreased use of axillary clearance, it remains a frequently performed operation. Axillary clearance is associated with moderate postoperative pain. We hypothesize that a continuous wound infusion of 0.2% Bupivacaine at 4ml/hr would provide superior analgesia, when compared to standard opioid-based analgesia, in patients undergoing axillary lymph node clearance surgery.

Detailed description

The study will take the form of a prospective randomised clinical trial. The following assessment tools will be used * The visual analogue scale (VAS) consists of a 100 mm horizontal line with the two end points labelled no pain and worst pain ever. Patients are asked to mark on the line a point that corresponds to the level of pain intensity they feel. The score is obtained by measuring the distance (mm) from the left end of the line. * The short-form McGill Pain Questionnaire (SF-MPQ) consists of 15 representative words from the sensory and affective categories of the standard McGill Pain Questionnaire. It also includes the present pain intensity and a VAS to provide overall indices of pain intensity. It has been shown to be sensitive to clinical changes brought about by various interventions, postoperative analgesic drugs (6). * The Pain Catastrophising Score (PCS) is a 13 item instrument which asks patient to reflect on past painful experiences, and to indicate the degree to which they experienced each of these 13 thoughts or feelings, on 5-point scales with the end points; 0 = not at all, 4 = all the time. The PCS yields a total score and three subscale scores assessing rumination, magnification and helplessness (7). * The Hospital Anxiety and Depression Score (HADS) is a 14-item scale, which screens for these, the two most common disturbances encountered in a medical setting (8).

Interventions

DRUGBupivacaine

intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively

Sponsors

Cork University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing axillary clearance surgery * ASA physical status I - III

Exclusion criteria

* Patient refusal * Pre-existing pain conditions * Regular use of opioid analgesia * Pregnancy * Severe cardiac, renal or hepatic disease * Psychiatric illness precluding ability to give informed consent * Intercurrent neurological disease * Contraindications to bupivacaine or morphine use

Design outcomes

Primary

MeasureTime frame
Pain on abducting the arm on the operative side to 90 degrees as measured using a 100mm visual analogue scale at 6 hours following surgery.6 hours postoperatively

Secondary

MeasureTime frame
Pain (at rest and on movement) in the recovery room and at 6, 24 and 48 hours after surgery.48 hours postoperatively
Cumulative Oxycodone consumption at 6, 24 and 48 hours after surgery48 hours postoperatively
incidence of nausea and vomiting48 hours postoperatively

Countries

Ireland

Contacts

Primary ContactDenise M McCarthy, MB FCARCSI
dmc_btown@yahoo.co.uk353 87 2341254
Backup ContactBrian O'Donnell, MD FCARCSI
briodnl@gmail.com353 21 4922135

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026